News
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time ...
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The ...
StockStory.org on MSN2d
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
Clinical Trials Arena on MSN6d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpointBioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...
RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on April 3 and set a price target of ...
Irish Examiner on MSN2h
'Half the place would be blown to bits': The Cork villages under threat from Trump’s tariffsCork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on ...
Donald Trump's tariffs threaten to decimate Ireland's pharmaceutical industry as the US President seeks to "force" companies ...
PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...
San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback